Fosun Pharma: Holding Subsidiary's Drug Receives Clinical Trial Approval

Fosun Pharma announced that its holding subsidiary, Shanghai Henlius Biotech, and its holding subsidiary have received approval from the National Medical Products Administration to conduct clinical trials for HLX37 injection in the treatment of advanced/metastatic solid tumors. HLX37 is a recombinant humanized dual-specific antibody targeting PD-L1 and VEGF, developed independently by the group, intended for the treatment of advanced/metastatic solid tumors. As of October 2025, the group's cumulative research and development investment in HLX37 is approximately 50.23 million yuan. According to the latest data from IQVIA MIDAS, sales of targeted PD-1/PD-L1 and VEGF dual-specific antibody products globally are estimated to be around 920,000 US dollars in 2024.